The interview aims to examine the newly presented two-year Phase 3 MAESTRO-NAFLD-1 data evaluating Rezdiffra (resmetirom), a liver-directed thyroid hormone receptor beta (THR-β) agonist, in patients with compensated metabolic dysfunction–associated steatohepatitis (MASH) cirrhosis. The discussion will focus on improvements in noninvasive imaging tests, fibrosis biomarkers, portal hypertension risk scores, and patient-reported quality-of-life outcomes, as well as the clinical implications of treatment interruption and the need for sustained therapy in advanced disease.